Gland Pharma Approves USD 21 Million Investment in US Expansion
Gland Pharma Ltd 路 Others (Uncategorized) 路 01 Oct 2026, 9:21 pm
Gland Pharma Approves USD 21 Million Investment in US Expansion Gland Pharma鈥檚 Board approved an investment of USD 21m in its wholly-owned subsidiary, Gland Pharma USA Inc., on 1st Oct'26 to acquire a 60% stake in newly incorporated Novelstar Pharma Inc. for USD 21m in cash by 31st Oct'26, expanding its US business. Fosun Pharma USA Inc. will hold the remaining 40%. Additionally, Wenjie Zhang resigned as Non-Executive Director effective 1st Oct'26, and Xingli Wang was appointed as Additional Non-Executive Director.
Original exchange filing (PDF)
More announcements from Gland Pharma Ltd
- Schedule of Investor Meet Intimation 路 17 Nov 2026
- Allotment of 3739 Equity Shares on exercise of ESOPs 路 16 Nov 2026
- Grant of Options to Purchase Securities 路 16 Nov 2026
- Q2FY27 Earnings Call Transcript 路 12 Nov 2026
- Gland Pharma Limited has issued Corporate Guarantee on behalf of Phixen SAS, wholly owned step down subsidiary of the Company 路 12 Nov 2026
- Appointment of Mr. Xiao Le as Chief Investment Officer at Gland Pharma International Pte. Ltd, wholly owned subsidiary of Gland Pharma Limited, effective November 09, 2026 路 09 Nov 2026
- Q2FY27 Earnings Call Recording 路 07 Nov 2026
- Q2Fy27 Investors presentation 路 06 Nov 2026
